Moderate-to-severe plaque psoriasis Skin and Connective Tissue Diseases
Conditions
Interventions
This is a multicentre sequential interventional study with two stages.
Stage 1 (induction stage): up to 200 eligible adults with moderate-to-severe plaque psoriasis will receive ixekizumab induction
Sponsors
Guangdong Provincial Hospital of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Adults aged 18 to 70 years 2. Diagnosis of moderate-to-severe plaque psoriasis 3. PASI score =7 or body surface area involvement=10% 4. Meets the indication criteria for ixekizumab treatment 5. Willing and able to provide written informed consent
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women, or participants planning pregnancy during the study period 2. Inflammatory bowel disease 3. Serious uncontrolled primary disease of the respiratory, cardiovascular or other major organ systems, or serious infection, tuberculosis, hepatitis, haematological abnormality, tumour, severe electrolyte or acid-base disturbance, primary or secondary immunodeficiency, severe psychiatric disease, or any clinically significant abnormal laboratory result judged by the investigator to make participation unsuitable 4. Known allergy or hypersensitivity to any study medication or its ingredients 5. Participation in another drug clinical trial currently or within the previous 4 weeks 6. Use of Chinese medicine or topical psoriasis treatments within 2 weeks before enrolment; oral systemic therapy or ultraviolet phototherapy within 4 weeks; or biologic therapy within 5 half-lives before enrolment 7. Any other condition judged by the investigator to make the participant unsuitable for the study
Countries
China
Contacts
Public ContactJingjie Yu
Outcome results
None listed